DAFNA Capital Management LLC cut its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) by 1.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 402,667 shares of the biopharmaceutical company’s stock after selling 3,868 shares during the quarter. Xenon Pharmaceuticals comprises approximately 3.2% of DAFNA Capital Management LLC’s holdings, making the stock its 5th largest holding. DAFNA Capital Management LLC’s holdings in Xenon Pharmaceuticals were worth $12,579,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Captrust Financial Advisors bought a new stake in shares of Xenon Pharmaceuticals during the third quarter worth $46,000. Macquarie Group Ltd. lifted its position in shares of Xenon Pharmaceuticals by 551.9% during the third quarter. Macquarie Group Ltd. now owns 3,514 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 2,975 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Xenon Pharmaceuticals by 104.1% during the fourth quarter. JPMorgan Chase & Co. now owns 4,775 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 119,961 shares during the period. Morgan Stanley increased its stake in shares of Xenon Pharmaceuticals by 101.7% during the first quarter. Morgan Stanley now owns 4,959 shares of the biopharmaceutical company’s stock valued at $89,000 after buying an additional 2,500 shares during the period. Finally, ProShare Advisors LLC purchased a new position in shares of Xenon Pharmaceuticals during the fourth quarter valued at $227,000.
XENE has been the topic of several research reports. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Wednesday, March 2nd. StockNews.com upgraded Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday. TheStreet upgraded Xenon Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Monday, March 14th. Wedbush reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Wednesday, March 2nd. Finally, Zacks Investment Research lowered Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 14th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus target price of $41.80.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.03. Xenon Pharmaceuticals had a negative net margin of 360.80% and a negative return on equity of 20.94%. During the same quarter in the previous year, the firm earned ($0.42) earnings per share. Equities analysts expect that Xenon Pharmaceuticals Inc. will post -2.04 EPS for the current year.
In related news, Director Simon N. Pimstone sold 31,086 shares of the firm’s stock in a transaction on Monday, March 7th. The shares were sold at an average price of $30.50, for a total transaction of $948,123.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James R. Empfield sold 32,853 shares of the firm’s stock in a transaction on Monday, March 7th. The stock was sold at an average price of $30.54, for a total transaction of $1,003,330.62. The disclosure for this sale can be found here. In the last three months, insiders have sold 94,974 shares of company stock valued at $2,899,047. 7.48% of the stock is currently owned by corporate insiders.
About Xenon Pharmaceuticals (Get Rating)
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
- Get a free copy of the StockNews.com research report on Xenon Pharmaceuticals (XENE)
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.